Novel findings in immunopathophysiology of chronic rhinosinusitis and their role in a model of precision medicine

被引：23
作者：
Xu, Xinni [1 ]
Ong, Yew Kwang [1 ]
Wang, De Yun [2 ]
机构：
[1] Natl Univ Hosp Syst, Dept Otolaryngol Head & Neck Surg, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore
来源：
ALLERGY | 2020年 / 75卷 / 04期
关键词：
biomarkers; chronic rhinosinusitis; endotypes; immunopathophysiology; precision medicine; EOSINOPHILIC CHRONIC RHINOSINUSITIS; INTERNATIONAL CONSENSUS STATEMENT; ENDOSCOPIC SINUS SURGERY; INNATE LYMPHOID-CELLS; NASAL POLYPS; ALLERGEN IMMUNOTHERAPY; REMODELED EPITHELIUM; RANDOMIZED PHASE-3; AIRWAY DISEASE; FOLLOW-UP;
D O I：
10.1111/all.14044
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Our understanding of the pathophysiology of chronic rhinosinusitis (CRS) is continuously evolving. The traditional description of CRS in terms of two phenotypes based on the presence or absence of nasal polyps belies the underlying intricate immunopathophysiological processes responsible for this condition. CRS is being increasingly recognized as a disease spectrum encompassing a range of inflammatory states in the sinonasal cavity, with non-type 2 inflammatory disease on one end, type 2 inflammatory, eosinophil-heavy disease on the other and an overlap of both in different proportions in between. Abundance in research on the immune mechanisms of CRS has revealed various new endotypes that hold promise as biomarkers for the development of targeted therapies in severe, uncontrolled CRS. The introduction of precision medicine to manage this chronic, complex condition is a step forward in providing individualized care for all patients with CRS. In this review, the latest research on the pathophysiology of CRS with a focus on potential novel biomarkers and treatment options over the last 2 years are summarized and integrated into a suggested model of precision medicine in CRS.
引用
收藏
页码：769 / 780
页数：12
相关论文
共 137 条
  • [1] Untangling asthma phenotypes and endotypes
    Agache, I.
    Akdis, C.
    Jutel, M.
    Virchow, J. C.
    [J]. ALLERGY, 2012, 67 (07) : 835 - 846
  • [2] Alpan O, 2019, ALLERGY
  • [3] Arebro J, 2019, ALLERGY
  • [4] Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug
    Asero, Riccardo
    [J]. ALLERGY, 2018, 73 (11) : 2242 - 2244
  • [5] A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps
    Bachert, Claus
    Desrosiers, Martin
    Mullol, Joaquim
    Hellings, Peter W.
    Cervin, Anders
    Sher, Lawrence
    Bosso, John V.
    Lee, Stella E.
    Maspero, Jorge F.
    Fujieda, Shigeharu
    Matsune, Shoji
    Lu, Xin
    Fan, Chunpeng
    Draikiwicz, Steven
    Amin, Nikhil
    Kamat, Siddhesh
    Khan, Asif
    Pirozzi, Gianluca
    Graham, Neil M. H.
    Ruddy, Marcella
    Staudinger, Heribert
    Mannent, Leda P.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB433 - AB433
  • [6] Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
    Bachert, Claus
    Sousa, Ana R.
    Lund, Valerie J.
    Scadding, Glenis K.
    Gevaert, Philippe
    Nasser, Shuaib
    Durham, Stephen R.
    Cornet, Marjolein E.
    Kariyawasam, Harsha H.
    Gilbert, Jane
    Austin, Daren
    Maxwell, Aoife C.
    Marshall, Richard P.
    Fokkens, Wytske J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (04) : 1024 - +
  • [7] Biology of the Eosinophil
    Blanchard, Carine
    Rothenberg, Marc E.
    [J]. ADVANCES IN IMMUNOLOGY, VOL 101, 2009, 101 : 81 - 121
  • [8] Neutrophils, from Marrow to Microbes
    Borregaard, Niels
    [J]. IMMUNITY, 2010, 33 (05) : 657 - 670
  • [9] Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study
    Bousquet, J.
    Caimmi, D. P.
    Bedbrook, A.
    Bewick, M.
    Hellings, P. W.
    Devillier, P.
    Arnavielhe, S.
    Bachert, C.
    Bergmann, K. C.
    Canonica, G. W.
    Chavannes, N. H.
    Cruz, A. A.
    Dahl, R.
    Demoly, P.
    De Vries, G.
    Mathieu-Dupas, E.
    Finkwagner, A.
    Fonseca, J.
    Guldemond, N.
    Haahtela, T.
    Hellqvist-Dahl, B.
    Just, J.
    Keil, T.
    Klimek, L.
    Kowalski, M. L.
    Kuitunen, M.
    Kuna, P.
    Kvedariene, V.
    Laune, D.
    Pereira, A. M.
    Carreiro-Martins, P.
    Melen, E.
    Morais-Almeida, M.
    Mullol, J.
    Muraro, A.
    Murray, R.
    Nogueira-Silva, L.
    Papadopoulos, N. G.
    Passalacqua, G.
    Portejoie, F.
    Price, D.
    Ryan, D.
    Samolinski, B.
    Sheikh, A.
    Siroux, V.
    Spranger, O.
    Bom, A. Todo
    Tomazic, P. V.
    Valero, A.
    Valovirta, E.
    [J]. ALLERGY, 2017, 72 (06) : 857 - 865
  • [10] Allergen Immunotherapy (AIT): a prototype of Precision Medicine
    Canonica, G. W.
    Bachert, C.
    Hellings, P.
    Ryan, D.
    Valovirta, E.
    Wickman, M.
    De Beaumont, O.
    Bousquet, J.
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2015, 8
12345678910